Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

Procedure coding in the American Joint Replacement Registry.

Cahue SR, Etkin CD, Stryker LS, Voss FR.

Arthroplast Today. 2019 May 30;5(2):251-255. doi: 10.1016/j.artd.2019.04.003. eCollection 2019 Jun.

2.

Local gastric RAAS inhibition improves gastric microvascular perfusion in dogs.

Truse R, Voß F, Herminghaus A, Schulz J, Weber APM, Mettler-Altmann T, Bauer I, Picker O, Vollmer C.

J Endocrinol. 2019 Jun 1;241(3):235-247. doi: 10.1530/JOE-19-0030.

PMID:
30978701
3.

Dose Determination for a Fixed-Dose Drug Combination: A Phase II Randomized Controlled Trial for Tiotropium/Olodaterol Versus Tiotropium in Patients with COPD.

Maltais F, Hamilton A, Voß F, Maleki-Yazdi MR.

Adv Ther. 2019 Apr;36(4):962-968. doi: 10.1007/s12325-019-00911-y. Epub 2019 Mar 6.

PMID:
30843141
4.

[Premature ventricular contractions and tachycardia in a structurally normal heart : Idiopathic PVC and VT].

Busch S, Eckardt L, Sommer P, Meyer C, Bonnemeier H, Thomas D, Neuberger HR, Tilz RR, Steven D, von Bary C, Kuniss M, Voss F, Estner HL.

Herzschrittmacherther Elektrophysiol. 2019 Jun;30(2):212-224. doi: 10.1007/s00399-019-0607-1. Epub 2019 Feb 14. German.

PMID:
30767064
5.

Effects of baseline symptom burden on treatment response in COPD.

Martinez FJ, Abrahams RA, Ferguson GT, Bjermer L, Grönke L, Voß F, Singh D.

Int J Chron Obstruct Pulmon Dis. 2019 Jan 4;14:181-194. doi: 10.2147/COPD.S179912. eCollection 2019.

6.

On estimands and the analysis of adverse events in the presence of varying follow-up times within the benefit assessment of therapies.

Unkel S, Amiri M, Benda N, Beyersmann J, Knoerzer D, Kupas K, Langer F, Leverkus F, Loos A, Ose C, Proctor T, Schmoor C, Schwenke C, Skipka G, Unnebrink K, Voss F, Friede T.

Pharm Stat. 2019 Mar;18(2):166-183. doi: 10.1002/pst.1915. Epub 2018 Nov 20.

7.

Intranasal Vaccination With Lipoproteins Confers Protection Against Pneumococcal Colonisation.

Voß F, Kohler TP, Meyer T, Abdullah MR, van Opzeeland FJ, Saleh M, Michalik S, van Selm S, Schmidt F, de Jonge MI, Hammerschmidt S.

Front Immunol. 2018 Oct 18;9:2405. doi: 10.3389/fimmu.2018.02405. eCollection 2018.

8.

Safety of tiotropium/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials.

Ferguson GT, Buhl R, Bothner U, Hoz A, Voß F, Anzueto A, Calverley PMA.

Respir Med. 2018 Oct;143:67-73. doi: 10.1016/j.rmed.2018.08.012. Epub 2018 Aug 28.

9.

Updated Survey on Interventional Electrophysiology: 5-Year Follow-Up of Infrastructure, Procedures, and Training Positions in Germany.

Eckardt L, Frommeyer G, Sommer P, Steven D, Deneke T, Estner HL, Kriatselis C, Kuniss M, Busch S, Tilz RR, Bonnemeier H, von Bary C, Voss F, Meyer C, Thomas D, Neuberger HR.

JACC Clin Electrophysiol. 2018 Jun;4(6):820-827. doi: 10.1016/j.jacep.2018.01.001. Epub 2018 Mar 1.

10.

Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia.

Ottmann OG, Müller-Tidow C, Krämer A, Schlenk RF, Lübbert M, Bug G, Krug U, Bochtler T, Voss F, Taube T, Liu D, Garin-Chesa P, Döhner H.

Br J Haematol. 2019 Mar;184(6):1018-1021. doi: 10.1111/bjh.15204. Epub 2018 Jun 8. No abstract available.

PMID:
29882583
11.

Pneumococcal Metabolic Adaptation and Colonization Are Regulated by the Two-Component Regulatory System 08.

Gómez-Mejia A, Gámez G, Hirschmann S, Kluger V, Rath H, Böhm S, Voss F, Kakar N, Petruschka L, Völker U, Brückner R, Mäder U, Hammerschmidt S.

mSphere. 2018 May 16;3(3). pii: e00165-18. doi: 10.1128/mSphere.00165-18. eCollection 2018 May-Jun.

12.

β-Blockers in COPD: A Cohort Study From the TONADO Research Program.

Maltais F, Buhl R, Koch A, Amatto VC, Reid J, Grönke L, Bothner U, Voß F, McGarvey L, Ferguson GT.

Chest. 2018 Jun;153(6):1315-1325. doi: 10.1016/j.chest.2018.01.008. Epub 2018 Jan 31.

13.

[The Medical Examination - Between Desire and Reality - Analysis of Consensus Between the Second Part of the Medical Licensing Exam (IMPP) and the National Catalogue of Expertise-based Learning Goals in Surgery (NKLC)].

Sterz J, Rüsseler M, Britz V, Stefanescu C, Hoefer SH, Adili F, Schreckenbach T, Schleicher I, Weber R, Hofmann HS, Voß F, König S, Heinemann MK, Kadmon M.

Zentralbl Chir. 2017 Dec;142(6):614-621. doi: 10.1055/s-0043-119995. Epub 2017 Dec 13. German.

PMID:
29237221
14.

Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat® device for maintenance treatment of COPD: comparison with the long-acting β2-agonist formoterol.

Koch A, Watz H, Maleki-Yazdi MR, Bothner U, Tetzlaff K, Voß F, McGarvey L.

NPJ Prim Care Respir Med. 2017 Oct 23;27(1):60. doi: 10.1038/s41533-017-0059-1.

15.

Effect of rotational prosthetic alignment variation on tibiofemoral contact pressure distribution and joint kinematics in total knee replacement.

Xie X, Rusly R, DesJardins JD, Voss F, Chillag K, LaBerge M.

Proc Inst Mech Eng H. 2017 Nov;231(11):1034-1047. doi: 10.1177/0954411917727564. Epub 2017 Aug 18.

PMID:
28820012
16.

Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies.

Ferguson GT, Karpel J, Bennett N, Clerisme-Beaty E, Grönke L, Voß F, Buhl R.

NPJ Prim Care Respir Med. 2017 Feb 2;27(1):7. doi: 10.1038/s41533-016-0002-x.

17.

Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease.

Buhl R, Magder S, Bothner U, Tetzlaff K, Voß F, Loaiza L, Vogelmeier CF, McGarvey L.

Respir Med. 2017 Jan;122:58-66. doi: 10.1016/j.rmed.2016.11.011. Epub 2016 Nov 14.

18.

Modular Architecture and Unique Teichoic Acid Recognition Features of Choline-Binding Protein L (CbpL) Contributing to Pneumococcal Pathogenesis.

Gutiérrez-Fernández J, Saleh M, Alcorlo M, Gómez-Mejía A, Pantoja-Uceda D, Treviño MA, Voß F, Abdullah MR, Galán-Bartual S, Seinen J, Sánchez-Murcia PA, Gago F, Bruix M, Hammerschmidt S, Hermoso JA.

Sci Rep. 2016 Dec 5;6:38094. doi: 10.1038/srep38094.

19.

[Implantable loop recorders of the Reveal family (Medtronic)].

Voss F.

Herzschrittmacherther Elektrophysiol. 2016 Dec;27(4):333-336. Epub 2016 Nov 22. Review. German.

PMID:
27878365
20.

[AV-reentrant tachycardia and Wolff-Parkinson-White syndrome : Diagnosis and treatment].

Voss F, Eckardt L, Busch S, Estner HL, Steven D, Sommer P, von Bary C, Neuberger HR.

Herzschrittmacherther Elektrophysiol. 2016 Dec;27(4):381-389. Epub 2016 Nov 22. Review. German.

PMID:
27878364
21.

Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO® and OTEMTO® studies: a subgroup analysis by age.

Ferguson GT, Karpel JP, Clerisme-Beaty E, Grönke L, Voß F, Buhl R.

Int J Chron Obstruct Pulmon Dis. 2016 Oct 31;11:2701-2710. eCollection 2016.

22.

The efficacy and safety of combined tiotropium and olodaterol via the Respimat(®) inhaler in patients with COPD: results from the Japanese sub-population of the Tonado(®) studies.

Ichinose M, Taniguchi H, Takizawa A, Grönke L, Loaiza L, Voß F, Zhao Y, Fukuchi Y.

Int J Chron Obstruct Pulmon Dis. 2016 Aug 29;11:2017-27. doi: 10.2147/COPD.S110389. eCollection 2016.

23.

Pneumococcal lipoproteins involved in bacterial fitness, virulence, and immune evasion.

Kohler S, Voß F, Gómez Mejia A, Brown JS, Hammerschmidt S.

FEBS Lett. 2016 Nov;590(21):3820-3839. doi: 10.1002/1873-3468.12352. Epub 2016 Aug 24. Review.

24.

Evaluation of the effects of olodaterol on exercise endurance in patients with chronic obstructive pulmonary disease: results from two 6-week crossover studies.

Maltais F, Kirsten AM, Hamilton A, De Sousa D, Voß F, Decramer M.

Respir Res. 2016 Jul 6;17(1):77. doi: 10.1186/s12931-016-0389-5.

25.

Inactivation and Anion Selectivity of Volume-regulated Anion Channels (VRACs) Depend on C-terminal Residues of the First Extracellular Loop.

Ullrich F, Reincke SM, Voss FK, Stauber T, Jentsch TJ.

J Biol Chem. 2016 Aug 12;291(33):17040-8. doi: 10.1074/jbc.M116.739342. Epub 2016 Jun 20.

26.

Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies.

Singh D, Gaga M, Schmidt O, Bjermer L, Grönke L, Voß F, Ferguson GT.

Respir Res. 2016 Jun 18;17(1):73. doi: 10.1186/s12931-016-0387-7.

27.

Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials.

Jensen DM, Asselah T, Dieterich D, Foster GR, Sulkowski MS, Zeuzem S, Mantry P, Yoshida EM, Moreno C, Ouzan D, Wright M, Morano LE, Buynak R, Bourlière M, Hassanein T, Nishiguchi S, Kao JH, Omata M, Paik SW, Wong DK, Tam E, Kaita K, Feinman SV, Stern JO, Scherer J, Quinson AM, Voss F, Gallivan JP, Böcher WO, Ferenci P.

Ann Hepatol. 2016 May-Jun;15(3):333-49. doi: 10.5604/16652681.1198803.

28.

[Typical atrial flutter: Diagnosis and therapy].

Thomas D, Eckardt L, Estner HL, Kuniss M, Meyer C, Neuberger HR, Sommer P, Steven D, Voss F, Bonnemeier H.

Herzschrittmacherther Elektrophysiol. 2016 Mar;27(1):46-56. doi: 10.1007/s00399-016-0413-y. Epub 2016 Feb 4. Review. German.

PMID:
26846223
29.

Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting β2-agonists: a systematic review and network meta-analysis.

Schlueter M, Gonzalez-Rojas N, Baldwin M, Groenke L, Voss F, Reason T.

Ther Adv Respir Dis. 2016 Apr;10(2):89-104. doi: 10.1177/1753465815624612. Epub 2016 Jan 8. Review.

30.

Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials.

Jensen DM, Asselah T, Dieterich D, Foster GR, Sulkowski MS, Zeuzem S, Mantry P, Yoshida EM, Moreno C, Ouzan D, Wright M, Morano LE, Buynak R, Bourlière M, Hassanein T, Nishiguchi S, Kao JH, Omata M, Paik SW, Wong DK, Tam E, Kaita K, Feinman SV, Stern JO, Scherer J, Quinson AM, Voss F, Gallivan JP, Böcher WO, Ferenci P.

Ann Hepatol. 2016 May - Jun;15(3):333-349. doi: 10.5604/16652681.1198803.

31.

Help, my rating looks bad! Coding comorbidities in arthroplasty.

Galloway JD, Voss FR.

Arthroplast Today. 2016 Aug 27;2(3):133-136. doi: 10.1016/j.artd.2016.03.003. eCollection 2016 Sep.

32.

ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection.

Asselah T, Zeuzem S, Soriano V, Bronowicki JP, Lohse AW, Müllhaupt B, Schuchmann M, Bourlière M, Buti M, Roberts SK, Gane EJ, Stern JO, Voss F, Baum P, Gallivan JP, Böcher WO, Mensa FJ.

PLoS One. 2015 Dec 9;10(12):e0144004. doi: 10.1371/journal.pone.0144004. eCollection 2015.

33.

VRAC: molecular identification as LRRC8 heteromers with differential functions.

Jentsch TJ, Lutter D, Planells-Cases R, Ullrich F, Voss FK.

Pflugers Arch. 2016 Mar;468(3):385-93. doi: 10.1007/s00424-015-1766-5. Epub 2015 Dec 3. Review.

PMID:
26635246
34.

[AV nodal reentrant tachycardia. Diagnosis and therapy].

von Bary C, Eckardt L, Steven D, Neuberger HR, Tilz RR, Bonnemeier H, Thomas D, Deneke T, Estner HL, Kuniss M, Luik A, Sommer P, Voss F, Meyer C, Shin DI, Kriatselis C.

Herzschrittmacherther Elektrophysiol. 2015 Dec;26(4):351-8. doi: 10.1007/s00399-015-0399-x. Review. German.

PMID:
26558907
35.

Subunit composition of VRAC channels determines substrate specificity and cellular resistance to Pt-based anti-cancer drugs.

Planells-Cases R, Lutter D, Guyader C, Gerhards NM, Ullrich F, Elger DA, Kucukosmanoglu A, Xu G, Voss FK, Reincke SM, Stauber T, Blomen VA, Vis DJ, Wessels LF, Brummelkamp TR, Borst P, Rottenberg S, Jentsch TJ.

EMBO J. 2015 Dec 14;34(24):2993-3008. doi: 10.15252/embj.201592409. Epub 2015 Nov 3.

36.

A risk assessment example for soil invertebrates using spatially explicit agent-based models.

Reed M, Alvarez T, Chelinho S, Forbes V, Johnston A, Meli M, Voss F, Pastorok R.

Integr Environ Assess Manag. 2016 Jan;12(1):58-66. doi: 10.1002/ieam.1713. Epub 2015 Dec 5.

PMID:
26411378
37.

Safety of symptom-limited exercise testing in a big cohort of a modern ICD population.

Voss F, Schueler M, Lauterbach M, Bauer A, Katus HA, Becker R.

Clin Res Cardiol. 2016 Jan;105(1):53-8. doi: 10.1007/s00392-015-0885-5. Epub 2015 Jun 30.

PMID:
26123830
38.

[How to approach the patient with supraventricular tachycardia in the EP lab: A systematic overview].

Steven D, Bonnemeier H, Deneke T, Estner HL, Kriatselis C, Kuniss M, Luik A, Neuberger HR, Shin DI, Sommer P, Tilz RR, Thomas D, von Bary C, Voss F, Eckardt L.

Herzschrittmacherther Elektrophysiol. 2015 Jun;26(2):167-72. doi: 10.1007/s00399-015-0373-7. Epub 2015 Jun 2. Review. German.

PMID:
26031513
39.

Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis.

Zeuzem S, Soriano V, Asselah T, Gane EJ, Bronowicki JP, Angus P, Lohse AW, Stickel F, Müllhaupt B, Roberts S, Schuchmann M, Manns M, Bourlière M, Buti M, Stern JO, Gallivan JP, Voss F, Sabo JP, Böcher W, Mensa FJ; SOUND-C2 Study Group.

Antimicrob Agents Chemother. 2015 Feb;59(2):1282-91. doi: 10.1128/AAC.04383-14. Epub 2014 Dec 15.

40.

Bacteriology of aspiration pneumonia in patients with acute coma.

Lauterbach E, Voss F, Gerigk R, Lauterbach M.

Intern Emerg Med. 2014 Dec;9(8):879-85. doi: 10.1007/s11739-014-1120-5. Epub 2014 Aug 28.

PMID:
25164409
41.

Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy.

Döhner H, Lübbert M, Fiedler W, Fouillard L, Haaland A, Brandwein JM, Lepretre S, Reman O, Turlure P, Ottmann OG, Müller-Tidow C, Krämer A, Raffoux E, Döhner K, Schlenk RF, Voss F, Taube T, Fritsch H, Maertens J.

Blood. 2014 Aug 28;124(9):1426-33. doi: 10.1182/blood-2014-03-560557. Epub 2014 Jul 8.

42.

Identification of LRRC8 heteromers as an essential component of the volume-regulated anion channel VRAC.

Voss FK, Ullrich F, Münch J, Lazarow K, Lutter D, Mah N, Andrade-Navarro MA, von Kries JP, Stauber T, Jentsch TJ.

Science. 2014 May 9;344(6184):634-8. doi: 10.1126/science.1252826. Epub 2014 Apr 10.

43.

A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies.

Lin CC, Su WC, Yen CJ, Hsu CH, Su WP, Yeh KH, Lu YS, Cheng AL, Huang DC, Fritsch H, Voss F, Taube T, Yang JC.

Br J Cancer. 2014 May 13;110(10):2434-40. doi: 10.1038/bjc.2014.195. Epub 2014 Apr 22.

44.

The use of local concentrated heat versus topical acyclovir for a herpes labialis outbreak: results of a pilot study under real life conditions.

Wohlrab J, Voß F, Müller C, Brenn LC.

Clin Cosmet Investig Dermatol. 2013 Nov 5;6:263-71. doi: 10.2147/CCID.S49273. eCollection 2013.

45.

A survey of German centres performing invasive electrophysiology: structure, procedures, and training positions.

Neuberger HR, Tilz RR, Bonnemeier H, Deneke T, Estner HL, Kriatselis C, Kuniss M, Luik A, Sommer P, Steven D, von Bary C, Voss F, Eckardt L.

Europace. 2013 Dec;15(12):1741-6. doi: 10.1093/europace/eut149. Epub 2013 Jun 4.

PMID:
23736806
46.

Occurrence of phrenic nerve stimulation in cardiac resynchronization therapy patients: the role of left ventricular lead type and placement site.

Biffi M, Exner DV, Crossley GH, Ramza B, Coutu B, Tomassoni G, Kranig W, Li S, Kristiansen N, Voss F.

Europace. 2013 Jan;15(1):77-82. doi: 10.1093/europace/eus237. Epub 2012 Jul 29.

PMID:
22848075
47.

Atrioventricular delay programming in cardiac resynchronization therapy devices: fixed or adaptive? A randomized monocenter trial.

Schueler M, Voss F, Bauer A, Thomas D, Kelemen K, Katus HA, Becker R.

J Electrocardiol. 2012 Nov-Dec;45(6):783-6. doi: 10.1016/j.jelectrocard.2012.05.005. Epub 2012 Jun 20.

PMID:
22727475
48.

Genetic suppression of Gαs protein provides rate control in atrial fibrillation.

Lugenbiel P, Thomas D, Kelemen K, Trappe K, Bikou O, Schweizer PA, Voss F, Becker R, Katus HA, Bauer A.

Basic Res Cardiol. 2012 May;107(3):265. doi: 10.1007/s00395-012-0265-5. Epub 2012 Mar 29.

PMID:
22457123
49.

[Is the determination of the defibrillation threshold in patients with an implantable cardioverter-defibrillator still required?].

Licka M, Jahn L, Kelemen K, Voss F, Trappe K, Becker R, Bikou O, Hauck M, Koch M, Katus HA, Bauer A.

Herzschrittmacherther Elektrophysiol. 2011 Dec;22(4):209-13. doi: 10.1007/s00399-011-0150-1. Epub 2011 Nov 13. German.

PMID:
22080419
50.

Clinical feasibility study for detection of myocardial oedema by a cine SSFP sequence in comparison to a conventional T2-weighted sequence.

Steen H, Voss F, André F, Neizel M, Schäufele T, Lehrke S, Lossnitzer D, Giannitsis E, Katus HA.

Clin Res Cardiol. 2012 Feb;101(2):125-31. doi: 10.1007/s00392-011-0373-5. Epub 2011 Oct 30.

PMID:
22038389

Supplemental Content

Support Center